Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 28 of 28 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/31/16
End: 05/19/17
Due: 05/19/18
Phase: N/A
Priority: Normal
Start: 12/22/14
End: 09/08/17
Due: 09/08/18
Phase: N/A
Priority: Normal
Start: 10/31/12
End: 01/31/16
Due: 01/31/17
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | NCT02722954 | OncoMed Pharmaceuticals, Inc. | user2@example.com | None | 2016-01-31 | 2017-05-19 | 2018-05-19 | - | - | 2025-07-14 |
| A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors | NCT02298387 | OncoMed Pharmaceuticals, Inc. | user2@example.com | None | 2014-12-22 | 2017-09-08 | 2018-09-08 | - | - | 2025-07-14 |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | OncoMed Pharmaceuticals, Inc. | user2@example.com | None | 2012-10-31 | 2016-01-31 | 2017-01-31 | - | - | 2025-07-14 |